Skip to content
Head to head

Ultragenyx Pharmaceutical vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: RARE · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

RARE -49.4%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (68); Vertex Pharmaceuticals has done best over the past year (+22%); Vertex Pharmaceuticals earns the most per share.
RAREVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price16.48515.02
Change today-4.30%-1.08%
1-year return-47.1%+22.0%
Market cap$1.68B$130.58B
52-week range12.73 – 39.89412.27 – 568.67
Valuation
P/E (TTM)-3.1933.14
P/E percentile, own 5-yr range96th99th
P/B-4.476.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-5.8315.32
Net profit (TTM)$-594.22M$3.88B
Revenue (TTM)$730.00M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+8.1%+11.8%
Gross margin82.9%85.5%
Operating margin-64.0%33.1%
Net margin-71.8%30.7%
Free cash flow (TTM)$-447.00M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership117.6%96.8%
Insider activity (12mo)30 buy / 20 sell28 buy / 22 sell
Short interest (% of float)24.0%1.9%
Analyst consensus47% buy / 53% hold (19)95% buy / 5% hold (21)
Analyst price target$25 (+54%)$624 (+21%)
StockVane view
StockVane Quant RatingE (7)C (68)
Company
Employees1,3716,400
Founded20101989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.